Avedro, Inc.

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking

Avedro Announces Its Second FDA Orphan Drug Designation for Corneal Cross-linking

December 7, 2011

Avedro, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s VibeX (riboflavin ophthalmic solution) for use with its KXL System (UVA irradiation) for Corneal Cross-linking to treat corneal ectasia following refractive surgery, such as Lasik and photorefractive keratectomy (PRK). Corneal ectasia is a rare outcome of refractive surgery but is a progressive condition that is difficult to manage. This is the company’s second orphan drug designation for VibeX.

Affinnova, Inc.

Affinnova to Continue Expansion in 2012

Affinnova to Continue Expansion in 2012

November 30, 2011

WALTHAM, MA, USA  – Due to increased demand, Affinnova, Inc., the global leader in marketing innovation software and services, will hire up to 70 new staff members in 2012. The announcement was made by Waleed Al-Atraqchi, president and chief executive officer of Affinnova.

BG Medicine, Inc.

BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

November 30, 2011

WALTHAM, Mass., (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today the availability of the peer-reviewed publication of the first clinical study on the role of galectin-3 in heart failure development.

Testing vaccine to block nicotine

Testing vaccine to block nicotine

November 27, 2011

What if there was a shot that you could get in a doctor’s office to negate the pleasurable effects of smoking a cigarette? It would last six months or a year, and then you might need a booster shot to prevent a relapse. Would you get it or recommend it to a family member or colleague who smokes? Would you give it to a teenage son or daughter who started hanging around with friends who smoke?
 

CEO Corner: Hiring Veterans

CEO Corner: Hiring Veterans

November 20, 2011

(NECN) - President Obama calls for the hiring of more Veterans, who have a disproportionately high jobless rate. 

Two men who are already committed to doing just that. 

Tom Pincince is President and CEO of Digital Lumens and Jim Matheson is a former Navy Pilot turned General Partner at Flagship Ventures. They will discuss why their companies hire Veterans.
 

Please click on NECN logo to view video

 

 

 

 

 

 

One-on-One with Dan Adelman of Alvine Pharmaceuticals

One-on-One with Dan Adelman of Alvine Pharmaceuticals

November 18, 2011

A gluten-free diet is great for celiac disease patients, but even the strictest adherents to dietary restrictions can experience flare ups or chronic symptoms.
 

Selecta Biosciences, Inc.

Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention

Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention

November 21, 2011

Watertown, MA – November 21, 2011 – Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.

LS9

LS9 Significantly Expands Production

LS9 Significantly Expands Production

November 7, 2011

LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced that it has successfully scaled its technology to the 20,000 liter scale, demonstrating continued progress in the scale-up and commercialization of its bio-based chemicals and fuels technology platform. From initial production of 1,000 liters at the Company's pilot plant in South San Francisco, California, LS9 has utilized a 20-fold step-up process to produce approximately one ton of a specific chemical for its strategic partner, Proctor & Gamble.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases

Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases

November 15, 2011

Lexington, MA – Concert Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Agios Secures $78 Million in Oversubscribed Series C Financing

Agios Secures $78 Million in Oversubscribed Series C Financing

November 17, 2011

Cambridge, Mass. – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that is has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.